Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Most effective anthrax treatment: VA-Stanford study finds

22.02.2006


When spores sent through the mail in 2001 caused 11 people to contract anthrax - ultimately killing five of them - infectious disease specialists noted that the death rate was substantially lower than the historical mortality rate, which approached 100 percent. Many assumed that access to modern intensive care units and more powerful antibiotics made the difference.



But after completing the most comprehensive review of anthrax cases ever conducted, researchers at the Veterans Affairs Palo Alto Health Care System and Stanford University School of Medicine have found that what most likely saved lives from the various anthrax mailings in Sept. 2001 was not advanced hospital care: It was rapid diagnosis and initiation of antibiotic treatment within the first few days of symptoms.

The researchers found that once anthrax progresses to its advanced stage, which typically occurs four days after the first symptoms, patients are almost certain to die from it, even if they receive the best care modern medicine has to offer. They also found that drainage of fluid from around the lungs is a key procedure associated with anthrax patients’ survival.


The study findings, published in the Feb. 21 issue of the Annals of Internal Medicine, underscore the importance of detecting anthrax early, educating medical personnel about its symptoms and treatment and ensuring efficient distribution systems that can deliver antibiotics to patients within hours of a bioterrorist attack. The findings also indicate that bioterrorism response stockpiles should include ample supplies of chest tubes used to perform fluid drainage - an intervention that has received relatively little attention in bioterrorism planning.

"Even with our modern intensive care, once you’ve reached the advanced stage of this disease, you’re probably going to die. That’s why it’s crucial to start antibiotics within the first few days," said lead author Jon-Erik Holty, MD, a fellow in pulmonary and critical-care medicine at Stanford, who did the research during a fellowship in health services research at the VA Palo Alto Health Care System.

Complicating matters, Holty noted, anthrax is difficult to diagnose. The disease’s early symptoms mimic the flu, and even in the later stages there is no quick, definitive test for it. For this reason, he said, "Doctors in the ER need to have a high degree of suspicion. They need to ask questions and notice patterns: Are a lot of patients getting flu symptoms in the summer? Is there a group of patients with these symptoms who were all in the same place?"

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. "It’s one of the main agents we’re worried about for bioterrorism, because it’s available, it can be weaponized, and it can do a spectacular amount of damage in a short period of time," said study senior author Douglas Owens, MD, a senior investigator at the VA Palo Alto and an associate professor of medicine at the Center for Health Policy/Center for Primary Care and Outcomes Research at Stanford. A few grams of anthrax spores could kill thousands of people within a week.

Anthrax progresses in two phases: an initial phase lasting about four days (called the prodromal phase), which produces flu-like symptoms including cough, fever, and chills; and an advanced phrase (the fulminant phase), which causes respiratory distress and shock.

While previous studies have examined up to 40 anthrax cases, the Stanford and VA researchers conducted a more comprehensive review, seeking all published reports of inhalational anthrax from 1900 to 2005 (anthrax could not be accurately diagnosed before 1900). The researchers sought to determine how patient characteristics, type of treatment given and the timing of treatment affect the course of the disease. They also aimed to compare the 2001 anthrax cases with all previous cases.

From an exhaustive search, they obtained reports of 82 confirmed cases of inhalational anthrax from 15 countries, including Russia, Germany, Uganda, Iran, Croatia, Turkey and Nairobi. All non-English reports were translated from their original languages. For each case, the researchers documented the year; the patient’s age, sex and nationality; the presenting symptoms and the stage at which anthrax was diagnosed; the type of treatment given and the timing of treatment; and whether the patient survived.

From their statistical analyses of all 82 cases, they found that the overall death rate was 85 percent, but for patients who progressed to the fulminant phase, the death rate was 97 percent, even among patients who received supportive care in a hospital ICU.

Timely antibiotic treatment was the key to patients’ survival. When antibiotics were begun within two days of initial symptoms, approximately 20 percent of patients died. When treatment was begun at four days, mortality was about 58 percent, and at six days it was nearly 80 percent. Multi-drug regimens were found to be more effective than single-drug regimens. And among all the anthrax patients who survived, 80 percent had fluid drained from around their lungs, a procedure known as pleural fluid drainage.

Comparing the 2001 anthrax cases with all others previously reported, researchers found that the 2001 patients were more likely to have started antibiotics during the prodromal phase, to have used multi-drug treatments and to have received pleural fluid drainage. Likely as a result, these patients were less likely to have progressed to the fulminant phrase and to have died.

Michelle Brandt | EurekAlert!
Further information:
http://www.stanford.edu
http://mednews.stanford.edu

More articles from Life Sciences:

nachricht Discovery of a Key Regulatory Gene in Cardiac Valve Formation
24.05.2017 | Universität Basel

nachricht Carcinogenic soot particles from GDI engines
24.05.2017 | Empa - Eidgenössische Materialprüfungs- und Forschungsanstalt

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

Physicists discover mechanism behind granular capillary effect

24.05.2017 | Physics and Astronomy

Measured for the first time: Direction of light waves changed by quantum effect

24.05.2017 | Physics and Astronomy

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>